Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Gliadel

- PMLiVE

FDA fast-tracks Astellas’ Rydapt rival

AML treatment gilteritinib is currently involved in four phase III trials

Bayer picks digital firms for open innovation support

Four new start-ups enter its Grants4Apps Accelerator programme

- PMLiVE

Bayer picks digital firms for open innovation support

Four new start-ups enter its Grants4Apps Accelerator programme

- PMLiVE

Xarelto no better than aspirin in secondary stroke study

The NOAC has 'very little' chance of showing overall benefit, says data monitoring committee

Bayer appoints new head of global innovation and development, consumer health

Dr Sharon James succeeds Dr John O’Mullane

- PMLiVE

NICE first fast-track appraisal backs Bayer’s Eylea

But company will have to reduce its cost through a patient access scheme

Bayer symbol

Bayer bags speedy US approval for lymphoma drug Aliqopa

FDA decision sets the pharma firm up for a showdown with Gilead's Zydelig

- PMLiVE

Bayer appoints Wolfgang Nickl as chief financial officer

He will succeed Johannes Dietsch on June 1, 2018

- PMLiVE

Takeda can’t sway NICE on oral myeloma therapy Ninlaro

Drug not recommended for NHS use in England and Wales

- PMLiVE

NICE reverses stance on Takeda’s Adcetris

But firm criticises final draft guidance's new restrictions on the non-Hodgkin’s lymphoma drug

- PMLiVE

Astellas extends phase III programme for Rydapt rival gilteritinib

Japanese group hopes its AML drug will soon compete with Novartis' recently-approved treatment

- PMLiVE

Samsung deal with Takeda looks beyond biosimilars

The duo plan to develop “multiple novel biologic therapies”

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links